The Prevalence and Risk Factors for Persistent Hyperparathyroidism in Post-Kidney Transplant Patients
A Single-Center Retrospective Study
DOI:
https://doi.org/10.15605/jafes.041.01.5475Keywords:
hyperparathyroidism, kidney transplantation, prevalence, risk factorsAbstract
Background. Persistent hyperparathyroidism (PHPT) remains a notable challenge among kidney transplant recipients due to its impact on calcium-phosphorus metabolism, potentially hindering recovery and long-term renal function. Understanding its prevalence and risk factors is vital for enhancing patient outcomes.
Objective. To determine the prevalence and identify risk factors for persistent hyperparathyroidism in adult Filipino kidney transplant recipients at a tertiary care hospital.
Methodology. A retrospective chart review was conducted for 80 kidney transplant recipients at Cardinal Santos Medical Center from January 1, 2014, to July 31, 2024. Data included demographics, comorbidities, medications, and laboratory profiles pre- and post-transplant.
Results. Persistent hyperparathyroidism was found in 58.8% of patients. Their mean age was 55.3 years, and 53.8% were male. Hypertension was present in 76.3%, and 60% had diabetes mellitus. Diabetic kidney disease was the leading cause of renal failure (57.5%). Post-transplant use of vitamin D supplements and calcimimetics increased by 31.3% and 26.3%, respectively. Pre-transplant hyperparathyroidism was a key risk factor, with a prevalence of 26.3%.
Conclusion. Regular monitoring and management of hyperparathyroidism are essential to improving long-term outcomes in kidney transplant recipients.
Downloads
References
Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of renal disease. Perm J. 2016;20(3):15-127. https://pubmed.ncbi.nlm.nih.gov/27479950 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991918 https://doi.org/10.7812/TPP/15-127
Abramyan S, Hanlon M. Kidney transplantation. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. https://pubmed.ncbi.nlm.nih.gov/33620832 NBK567755. Accessed October 1, 2024.
Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end-stage renal disease: Trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol. 2001;12(6):1293-6. https://pubmed.ncbi.nlm.nih.gov/11373354
https://doi.org/10.1681/ASN.V1261293
Tonelli M, Wiebe N, Knoll G, et al. Systematic review: Kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11(10):2093-109. https://pubmed.ncbi.nlm.nih.gov/21883901 https://doi.org/10.1111/j.1600-6143.2011.03686.x
Lou I, Foley D, Odorico SK, et al. How well does renal transplantation cure hyperparathyroidism? Ann Surg. 2015;262(4):653-9. https://pubmed.ncbi.nlm.nih.gov/26366545 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576689
https://doi.org/10.1097/SLA.0000000000001431
Evenepoel P. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin Nephrol. 2013;33(2):191-203. https://pubmed.ncbi.nlm.nih.gov/23465505 https://doi.org/10.1016/j.semnephrol.2012.12.019
Pihlstrøm H, Dahle DO, Mjøen G, et al. Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation. 2015;99(2):351-9. https://pubmed.ncbi.nlm.nih.gov/25594550 https://doi.org/10.1097/TP.0000000000000583
Araujo MJCLN, Ramalho JAM, Elias RM, et al. Persistent hyperparathyroidism as a risk factor for long-term graft failure: The need to discuss indication for parathyroidectomy. Surgery. 2018;163(5):1144-50. https://pubmed.ncbi.nlm.nih.gov/29331397
https://doi.org/10.1016/j.surg.2017.12.010
Cruzado JM, Moreno P, Torregrosa JV, et al. A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J Am Soc Nephrol. 2016;27(8):2487-94. https://pubmed.ncbi.nlm.nih.gov/26647424 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978046 https://doi.org/10.1681/ASN.2015060622
See A, Lim AEL, Wong J, et al. The effect of parathyroidectomy on patients' symptoms in tertiary hyperparathyroidism. Head Neck. 2019;41(8):2748-55. https://pubmed.ncbi.nlm.nih.gov/30957315 https://doi.org/10.1002/hed.25750
Sutton W, Chen X, Patel P, et al. Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients. Surgery. 2022;171(1):69-76. https://pubmed.ncbi.nlm.nih.gov/34266650 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688275
https://doi.org/10.1016/j.surg.2021.03.067
Dulfer RR, Franssen GJH, Hesselink DA, et al. Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. Br J Surg. 2017;104(7):804-13. https://pubmed.ncbi.nlm.nih.gov/28518414 https://doi.org/10.1002/bjs.10554
Tseng PY, Yang WC, Yang CY, et al. Long-term outcomes of parathyroidectomy in kidney transplant recipients with persistent hyperparathyroidism. Kidney Blood Press Res. 2015;40(4):386-94. https://pubmed.ncbi.nlm.nih.gov/26184764 https://doi.org/10.1159/000368514
Pitt SC, Sippel RS, Chen H. Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am. 2009;89(5):1227-39. https://pubmed.ncbi.nlm.nih.gov/19836494 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905047
https://doi.org/10.1016/j.suc.2009.06.011
Finnerty BM, Chan TW, Jones G, et al. Parathyroidectomy versus cinacalcet in the management of tertiary hyperparathyroidism: Surgery improves renal transplant allograft survival. Surgery. 2019;165(1):129-34. https://pubmed.ncbi.nlm.nih.gov/30415867
https://doi.org/10.1016/j.surg.2018.04.090
Roodnat JI, van Gurp EAFJ, Mulder PGH, et al. High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation. Transplantation. 2006;82(3):362-7. https://pubmed.ncbi.nlm.nih.gov/16906034 https://doi.org/10.1097/01.tp.0000228923.75739.88
Callender GG, Malinowski J, Javid M, et al. Parathyroidectomy prior to kidney transplant decreases graft failure. Surgery. 2017;161(1):44-50. https://pubmed.ncbi.nlm.nih.gov/27863776 https://doi.org/10.1016/j.surg.2016.10.003
Bonarek H, Merville P, Bonarek M, et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int. 1999;56(2):642-9. https://pubmed.ncbi.nlm.nih.gov/10432404 https://doi.org/10.1046/j.1523-1755.1999.00589.x
Torres A, Rodríguez AP, Concepción MT, et al. Parathyroid function in long-term renal transplant patients: Importance of pre-transplant PTH concentrations. Nephrol Dial Transplant. 1998;13 Suppl 3:94-7. https://pubmed.ncbi.nlm.nih.gov/9568830
https://doi.org/10.1093/ndt/13.suppl_3.94
Reinhardt W, Bartelworth H, Jockenhövel F, et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant. 1998;13(2):436-42. https://pubmed.ncbi.nlm.nih.gov/9509459 https://doi.org/10.1093/oxfordjournals.ndt.a027843
Messa P, Sindici C, Cannella G, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int. 1998;54(5):1704-13. https://pubmed.ncbi.nlm.nih.gov/9844148 https://doi.org/10.1046/j.1523-1755.1998.00142.x
Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol Dial Transplant. 2004;19(5):1281-7. https://pubmed.ncbi.nlm.nih.gov/14993493
https://doi.org/10.1093/ndt/gfh128
Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: A summary. Kidney Int. 2010;77(4):299-311. https://pubmed.ncbi.nlm.nih.gov/19847156 https://doi.org/10.1038ki.2009.377
Yamamoto T, Tominaga Y, Okada M, et al. Characteristics of persistent hyperparathyroidism after renal transplantation. World J Surg. 2016;40(3):600-6. https://pubmed.ncbi.nlm.nih.gov/26546189 https://doi.org/10.1007/s00268-015-3314-z
Egli H, Burla N, Breuer E, et al. Persisting hypercalcemia and hyperparathyroidism after kidney transplantation have a negative impact on graft and patient survival. Diagnostics (Basel). 2024;14(13):1358. https://pubmed.ncbi.nlm.nih.gov/39001249 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11240723 https://doi.org/10.3390/diagnostics14131358
Miedziaszczyk M, Lacka K, Tomczak O, Bajon A, Primke M, Idasiak-Piechocka I. Systematic review of the treatment of persistent hyperparathyroidism following kidney transplantation. Biomedicines. 2022;11(1):25. https://pubmed.ncbi.nlm.nih.gov/36672533
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855347 https://doi.org/10.3390/biomedicines11010025
Wang R, Reed RD, Price G, et al. Treatment of hypercalcemic hyperparathyroidism after kidney transplantation is associated with improved allograft survival. Oncologist. 2024;29(4):e467-74. https://pubmed.ncbi.nlm.nih.gov/38006197
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10994253 https://doi.org/10.1093/oncolo/oyad314
Moura AF, Moura-Neto JA, Requião-Moura LR, et al. Preemptive kidney transplantation: Why, when, and how? J Bras Nefrol. 2023;45(3):357-64. https://pubmed.ncbi.nlm
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Pamela Anne Gaerlan, Harold Henrison Chiu, Matt Jayson Fontarum, Jocelyn Cobankiat
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.
To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.
A written agreement will be issued to the requester once permission has been granted.
